COVID‐19 patients often show high‐titer non‐platelet‐activating anti‐PF4/heparin IgG antibodies
Justine Brodard, Johanna A. Kremer Hovinga, Pierre Fontana, Jan–Dirk Studt, Yves Gruel, Andreas Greinacher
Topics & Concepts
Platelet factor 4Coronavirus disease 2019 (COVID-19)AntibodyHeparinTiterMedicineHeparin-induced thrombocytopenia2019-20 coronavirus outbreakVirologyPlateletSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyInternal medicineDiseaseInfectious disease (medical specialty)OutbreakHeparin-Induced Thrombocytopenia and ThrombosisIntramuscular injections and effectsSARS-CoV-2 and COVID-19 Research